T cell receptor gene therapy for cancer.
T cell-based adoptive immunotherapy has been shown to be a promising treatment for various types of cancer. However, adoptive T cell therapy currently requires the custom isolation and characterization of tumor-specific T cells from each patient-a process that can be not only difficult and time-consuming but also often fails to yield high-avidity T cells, which together have limited the broad application of this approach as a clinical treatment. Employing T cell receptor (TCR) gene therapy as a component of adoptive T cell therapy strategies can overcome many of these obstacles, allowing autologous T cells with a defined specificity to be generated in a much shorter time period. Initial studies using this approach have been hampered by a number of technical difficulties resulting in low TCR expression and acquisition of potentially problematic specificities due to mispairing of introduced TCR chains with endogenous TCR chains. The last several years have seen substantial progress in our understanding of the multiple facets of TCR gene therapy that will have to be properly orchestrated for this strategy to succeed. Here we outline the challenges of TCR gene therapy and the advances that have been made toward realizing the promise of this approach.
Schmitt
Thomas M
TM
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Ragnarsson
Gunnar B
GB
Greenberg
Philip D
PD
D000915:Antibody Affinity / Q000276:immunology; D005786:Gene Expression Regulation / Q000502:physiology; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology / Q000627:therapeutic use*; D012190:Retroviridae
D011948:Receptors, Antigen, T-Cell
J Clin Oncol. 1997 Feb;15(2):433-44
9053463
Mol Ther. 2003 Jun;7(6):827-38
12788657
Gene Ther. 2009 Aug;16(8):1042-9
19494842
Mol Ther. 2009 Apr;17(4):742-9
19209146
J Gen Virol. 2001 May;82(Pt 5):1013-1025
11297676
Blood. 1995 Sep 1;86(5):2041-50
7655033
Science. 2006 Oct 6;314(5796):126-9
16946036
Science. 2003 Jun 13;300(5626):1749-51
12805549
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
15980149
J Virol. 2000 Sep;74(17):8207-12
10933734
Proc Natl Acad Sci U S A. 2005 May 31;102(22):7934-9
15908507
Nat Immunol. 2002 Oct;3(10):903-10
12352967
Prog Clin Biol Res. 1987;244:401-8
3310002
Nat Biotechnol. 2004 May;22(5):589-94
15064769
Nature. 1986 Mar 20-26;320(6059):232-8
2421164
J Clin Invest. 2005 Jun;115(6):1616-26
15931392
Hum Gene Ther. 2009 Jun;20(6):630-40
19265475
Nat Biotechnol. 2005 Mar;23(3):349-54
15723046
J Virol. 2008 Mar;82(6):3078-89
18184707
Nature. 1990 Dec 6;348(6301):552-4
2247164
Cancer Gene Ther. 2009 Feb;16(2):171-83
18690205
Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2140-5
11854510
J Clin Oncol. 2005 Apr 1;23(10):2346-57
15800326
J Immunol. 2005 Mar 1;174(5):2849-59
15728495
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5387-92
10779548
Nat Methods. 2006 Mar;3(3):191-7
16489336
Hum Gene Ther. 2005 Nov;16(11):1241-6
16259557
Nat Clin Pract Oncol. 2006 Dec;3(12):668-81
17139318
J Immunol. 2008 Aug 15;181(4):2563-71
18684947
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7
12682289
Cell Immunol. 2007 Jun;247(2):95-102
17897636
J Immunol. 2008 May 15;180(10):6536-43
18453572
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5651-6
10318939
Nat Rev Cancer. 2004 May;4(5):371-80
15122208
Cancer Res. 2006 Sep 1;66(17):8878-86
16951205
Blood. 2007 Mar 15;109(6):2331-8
17082316
J Gen Virol. 1991 Nov;72 ( Pt 11):2727-32
1658199
J Immunother. 2003 Jan-Feb;26(1):1-11
12514424
Hum Gene Ther. 2004 Jul;15(7):648-58
15242525
Protein Eng. 2003 Sep;16(9):707-11
14560057
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
12427970
J Clin Invest. 2008 Jan;118(1):294-305
18060041
Mol Ther. 2000 Apr;1(4):376-82
10933956
J Virol. 1999 Apr;73(4):2886-92
10074136
Nat Immunol. 2001 Oct;2(10):957-61
11577349
Adv Immunol. 1991;49:281-355
1853786
Trends Biotechnol. 2004 Jul;22(7):346-53
15245907
Mol Ther. 2002 Nov;6(5):615-26
12409260
Hum Gene Ther. 1998 Jul 1;9(10):1457-67
9681417
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74
14762166
Blood. 2009 Sep 17;114(12):2417-26
19605850
Virology. 1992 Oct;190(2):754-62
1325705
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9624-9
8790380
Eur J Immunol. 2006 Nov;36(11):3052-9
17051621
Nat Genet. 2000 Jun;25(2):217-22
10835641
Rev Med Virol. 2001 Jul-Aug;11(4):205-17
11479927
Clin Immunol. 2006 May;119(2):135-45
16458072
Nat Biotechnol. 2006 Jun;24(6):687-96
16732270
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1547-52
9990061
Immunity. 2001 Jul;15(1):71-82
11485739
J Clin Invest. 2007 Aug;117(8):2225-32
17671652
Nat Med. 1996 Feb;2(2):216-23
8574968
Blood. 2005 Jul 15;106(2):470-6
15790789
Annu Rev Immunol. 2004;22:745-63
15032595
Adv Cancer Res. 2003;88:53-99
12665053
J Immunol. 1999 Jul 1;163(1):507-13
10384155
J Immunother. 2008 Jan;31(1):1-6
18157006
J Immunol. 2008 Jun 1;180(11):7736-46
18490778
J Exp Med. 2009 Feb 16;206(2):463-75
19171765
N Engl J Med. 2008 Jun 19;358(25):2698-703
18565862
Blood. 2003 Jul 15;102(2):497-505
12649146
J Immunol. 2008 Jan 1;180(1):391-401
18097040